Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Other Accumulated Expenses (2020 - 2025)

Bolt Biotherapeutics' Other Accumulated Expenses history spans 6 years, with the latest figure at $500000.0 for Q2 2025.

  • For Q2 2025, Other Accumulated Expenses rose 12.11% year-over-year to $500000.0; the TTM value through Jun 2025 reached $500000.0, up 12.11%, while the annual FY2024 figure was $380000.0, 33.8% down from the prior year.
  • Other Accumulated Expenses for Q2 2025 was $500000.0 at Bolt Biotherapeutics, down from $526000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $1.5 million in Q2 2021 and bottomed at $373000.0 in Q3 2024.
  • The 5-year median for Other Accumulated Expenses is $814000.0 (2021), against an average of $781076.9.
  • The largest annual shift saw Other Accumulated Expenses surged 106.91% in 2021 before it tumbled 46.0% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $1.2 million in 2021, then fell by 19.62% to $963000.0 in 2022, then plummeted by 40.39% to $574000.0 in 2023, then crashed by 33.8% to $380000.0 in 2024, then surged by 31.58% to $500000.0 in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Other Accumulated Expenses are $500000.0 (Q2 2025), $526000.0 (Q1 2025), and $380000.0 (Q4 2024).